Medical devices, healthcare technology and the business of care
510(k) clearance · K262156

Anti-HCV Next

ABBOTT LABORATORIES · Decision date Sep 23, 2026

MEDTECHLEDGER EXPLANATIONK262156

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 09/23/2026 for the 510(k) K262156, submitted by Abbott Laboratories for a device named Anti-HCV Next. The application was received 06/26/2026 and reviewed under regulation 866.3169, product code MZO, in the Microbiology specialty and review panel. The public record lists the device classification as Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus, and describes the submission as a traditional 510(k) not reviewed by a third party.

SESE denotes 510(k) clearance rather than premarket approval. The record states no combination product and no authorized predetermined change control plan, and it does not identify a specific modified component or describe performance data, so the technical basis for the clearance and any labeling remain unknown from this page.

The page was last updated 10/26/2026. No decision summary content, indications, or analytical performance information appears in the available text.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Sep 23, 2026
FDA decision documents: 510(k) Premarket Notification - FDA

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262156
Regulatory pathway
510(k) premarket notification
Product code
MZO
Decision code
SESE
Decision date
Sep 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus.

Product code
MZO
FDA device class
2

FDA decision timeline

  1. K262156 received

    Application receipt date recorded by FDA.

  2. K262156 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ABBOTT LABORATORIES

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Abbott Park, IL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records